Aileron Therapeutics Inc., of Cambridge, Mass., dosed the first patients in a phase I trial of ALRN-6924, a potent and specific re-activator of the tumor suppressor protein known as wild type p53. ALRN-6924 binds equipotently and inhibits both of the p53 suppressor proteins, MDM2 and MDMX.